NCT01587586 - Dose Finding Study of Pegylated-P-Interferon-alpha-2b(P1101) in Treatment-Naive Subjects With Hepatitis C Virus Genotype 1 Infection | Biotech Hunter

Enrollment

107

Participants

Timeline

Start Date

October 18, 2011

Primary Completion Date

November 22, 2016

Study Completion Date

November 22, 2016

Conditions

Hepatitis C, Chronic

Interventions

BIOLOGICAL

PEGASYS 180 µg Q1W

48 doses, solution, 48 weeks

BIOLOGICAL

P1101 180 µg Q1W, 48 doses

48 doses, solution, 48 weeks

BIOLOGICAL

P1101 270µg Q1W, 48 doses

48 doses, solution, 48 weeks

BIOLOGICAL

P1101 450µg Q2W, 24 doses

24 doses, solution, 48 weeks

Trial Locations (13)

100

National Taiwan University Hospital, Taipei

106

Cathay General Hospital, Taipei

112

Taipei Veterans General Hospital, Taipei

204

Chang Gung Medical Foundation - Keelung, Keelung

220

Far Eastern Memorial Hospital, New Taipei City

231

Buddhist Tzu Chi General Hospital, Sindian City

333

Chang Gung Medical Foundation - Linkou, Linkou District

404

China Medical University Hospital, Taichung

407

Taichung Veterans General Hospital, Taichung

500

Changhua Christian Hospital, Changhua

640

National Taiwan University Hospital - Yunlin, Douliu

807

Kaohsiung Medical University Chung-Ho Memorial Hospital, Kaohsiung City

833

Chang Gung Medical Foundation - Kaohsiung, Kaohsiung City